Nasdaq · Common stock
Scribe Therapeutics (SCTX)
$15.60 +$0.20 (+1.27%)
- Day’s range
- $14.88–$16.89
- Volume
- 348,498
SCTX price history
SCTX closed at $15.60 on Oct. 26, 2026. Over the past year, its daily close ranged from $15.41 on Oct. 23, 2026 to $37.25 on Aug. 24, 2026.
Data table: SCTX daily closes, the past year
| Date | Close |
|---|---|
| Oct. 26, 2026 | $15.60 |
| Oct. 23, 2026 | $15.41 |
| Oct. 22, 2026 | $17.96 |
| Oct. 21, 2026 | $19.30 |
| Oct. 20, 2026 | $19.81 |
| Oct. 19, 2026 | $19.39 |
| Oct. 16, 2026 | $20.08 |
| Oct. 15, 2026 | $20.72 |
| Oct. 14, 2026 | $20.77 |
| Oct. 13, 2026 | $19.12 |
| Oct. 12, 2026 | $20.67 |
| Oct. 9, 2026 | $21.17 |
| Oct. 8, 2026 | $19.23 |
| Oct. 7, 2026 | $17.57 |
| Oct. 6, 2026 | $16.33 |
| Oct. 5, 2026 | $16.21 |
| Oct. 2, 2026 | $16.79 |
| Oct. 1, 2026 | $17.18 |
| Sept. 30, 2026 | $18.41 |
| Sept. 29, 2026 | $23.03 |
| Sept. 28, 2026 | $21.77 |
| Sept. 25, 2026 | $21.28 |
| Sept. 24, 2026 | $21.61 |
| Sept. 23, 2026 | $26.53 |
| Sept. 22, 2026 | $28.07 |
| Sept. 21, 2026 | $28.05 |
| Sept. 18, 2026 | $33.00 |
| Sept. 17, 2026 | $32.14 |
| Sept. 16, 2026 | $29.10 |
| Sept. 15, 2026 | $31.66 |
| Sept. 14, 2026 | $29.42 |
| Sept. 11, 2026 | $29.74 |
| Sept. 10, 2026 | $29.47 |
| Sept. 9, 2026 | $29.41 |
| Sept. 8, 2026 | $31.34 |
| Sept. 4, 2026 | $28.67 |
| Sept. 3, 2026 | $30.81 |
| Sept. 2, 2026 | $30.90 |
| Sept. 1, 2026 | $29.00 |
| Aug. 31, 2026 | $30.54 |
| Aug. 28, 2026 | $28.44 |
| Aug. 27, 2026 | $28.84 |
| Aug. 26, 2026 | $31.70 |
| Aug. 25, 2026 | $31.21 |
| Aug. 24, 2026 | $37.25 |
| Aug. 21, 2026 | $34.13 |
| Aug. 20, 2026 | $32.83 |
| Aug. 19, 2026 | $31.05 |
| Aug. 18, 2026 | $27.11 |
| Aug. 17, 2026 | $21.19 |
| Aug. 14, 2026 | $20.73 |
| Aug. 13, 2026 | $20.37 |
| Aug. 12, 2026 | $23.01 |
| Aug. 11, 2026 | $23.44 |
| Aug. 10, 2026 | $24.93 |
| Aug. 7, 2026 | $26.00 |
| Aug. 6, 2026 | $25.41 |
| Aug. 5, 2026 | $23.80 |
| Aug. 4, 2026 | $22.06 |
| Aug. 3, 2026 | $20.84 |
| July 31, 2026 | $19.48 |
| July 30, 2026 | $20.40 |
| July 29, 2026 | $18.36 |
| July 28, 2026 | $18.06 |
| July 27, 2026 | $18.97 |
| July 24, 2026 | $21.65 |
Key figures
- Average daily volume
- 363,480Past 3 months
- Market value
- $295.3M
- Dividend yield
- —
Price change
- 1 month
- −26.69%
- 3 months
- −27.94%
What Wall Street says about SCTX
In the past 90 days, Wall Street firms published 5 rating or price-target actions on SCTX: 4 new ratings and 1 reiterated rating.
| Action | Rating | |||
|---|---|---|---|---|
| HC Wainwright & Co. | Reiterates | Buy | $60 | |
| HC Wainwright & Co. | Initiates coverage | Buy | $60 | |
| Guggenheim | Initiates coverage | Buy | $50 | |
| Leerink Partners | Initiates coverage | Outperform | $37 | |
| Wells Fargo | Initiates coverage | Overweight | $60 |
Ratings and price targets are the firms’ own opinions, reported as published.
Not investment advice.
About Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
- Headquarters
- Alameda, Calif.
- Listed
- July 24, 2026
- Sector
- Health care
- Industry
- Biological products, (no diagnostic substances)
In WallStreetDigest editions
No WallStreetDigest article about SCTX is on the site yet.